Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.

Shi, Wei

Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. [electronic resource] - Leukemia research Jun 2012 - 749-55 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1873-5835

10.1016/j.leukres.2012.01.027 doi


Animals
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Murine-Derived--administration & dosage
Antigens, CD20--immunology
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Apoptosis--drug effects
Cell Line, Tumor
Drug Synergism
Histone Deacetylase Inhibitors--administration & dosage
Humans
Hydroxamic Acids--administration & dosage
Lymphoma, Mantle-Cell--drug therapy
Male
Mice
Mice, SCID
Rituximab
Vorinostat
Xenograft Model Antitumor Assays